EFFECT OF SIMVASTATIN THERAPY ON INDICATORS OF TRANSMITRAL BLOOD FLOW IN PATIENTS WITH DIASTOLIC HEART FAILURE

Aim. To study the effect of simvastatin added to standard therapy on the left ventricular structure functional status in patients with diastolic chronic heart failure (CHF).Material and methods. Patients (n=125) with diastolic CHF (relaxation disturbances and pseudonormalization) were included into the open nonrandomized study. Patients of the main group (n=66) received simvastatin additionally to standard therapy of CHF. Patients of control group (n=59) received standard therapy only. Initially and after 6 months of treatment Doppler echocardiography (EchoCG) was performed with assessment of transmitral blood flow indices. On the basis of EchoCG data diastolic dysfunction types were determined in patients of the main group. Dynamics of EchoCG indices were evaluated in accordance with these types.Results. Significant increase in E (peak early diastolic left ventricular filling velocity) value by 14.1% (p<0.001) and E/A (where A - peak left ventricular filling velocity at atrial contraction) ratio by 18.7% (p<0.001) was found in the main group in estimating of transmitral flow indicators. Deceleration time of early diastolic filling significantly decreased by 7.8% (p<0.01). Other parameters did not change significantly both in the main and control groups. Intra-group comparison in the main group demonstrated that transmitral blood flow indices changed significantly only in patients with delayed relaxation (type I of diastolic dysfunction).Conclusion. Simvаstatin added to standard therapy of CHF resulted in significant improvement in the left ventricle diastolic function

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

Aims The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Methods and results Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (inhospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, prehospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. Conclusion The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality